These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 28552799)

  • 1. An explorative analysis of process and formulation variables affecting comilling in a vibrational mill: The case of praziquantel.
    Beatrice Perissutti ; Passerini N; Trastullo R; Keiser J; Zanolla D; Zingone G; Voinovich D; Albertini B
    Int J Pharm; 2017 Nov; 533(2):402-412. PubMed ID: 28552799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Mechanochemistry and Spray Congealing for New Praziquantel Pediatric Formulations in Schistosomiasis Treatment.
    Albertini B; Perissutti B; Bertoni S; Zanolla D; Franceschinis E; Voinovich D; Lombardo F; Keiser J; Passerini N
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30870971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected solvent impact in the crystallinity of praziquantel/poly(vinylpyrrolidone) formulations. A solubility, DSC and solid-state NMR study.
    Costa ED; Priotti J; Orlandi S; Leonardi D; Lamas MC; Nunes TG; Diogo HP; Salomon CJ; Ferreira MJ
    Int J Pharm; 2016 Sep; 511(2):983-93. PubMed ID: 27506511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring mechanochemical parameters using a DoE approach: Crystal structure solution from synchrotron XRPD and characterization of a new praziquantel polymorph.
    Zanolla D; Perissutti B; Vioglio PC; Chierotti MR; Gigli L; Demitri N; Passerini N; Albertini B; Franceschinis E; Keiser J; Voinovich D
    Eur J Pharm Sci; 2019 Dec; 140():105084. PubMed ID: 31626966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Milling and comilling Praziquantel at cryogenic and room temperatures: Assessment of the process-induced effects on drug properties.
    Zanolla D; Perissutti B; Passerini N; Invernizzi S; Voinovich D; Bertoni S; Melegari C; Millotti G; Albertini B
    J Pharm Biomed Anal; 2018 May; 153():82-89. PubMed ID: 29462783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new soluble and bioactive polymorph of praziquantel.
    Zanolla D; Perissutti B; Passerini N; Chierotti MR; Hasa D; Voinovich D; Gigli L; Demitri N; Geremia S; Keiser J; Cerreia Vioglio P; Albertini B
    Eur J Pharm Biopharm; 2018 Jun; 127():19-28. PubMed ID: 29409939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and bioavailability of different praziquantel brands.
    Botros S; El-Lakkany N; Seif el-Din SH; Sabra AN; Ibrahim M
    Exp Parasitol; 2011 Feb; 127(2):515-21. PubMed ID: 21044626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCR synthesis of praziquantel derivatives.
    Liu H; William S; Herdtweck E; Botros S; Dömling A
    Chem Biol Drug Des; 2012 Apr; 79(4):470-7. PubMed ID: 22151001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparticulate system combining taste masking and immediate release properties for the aversive compound praziquantel.
    Münster M; Schoch C; Schmidt C; Breitkreutz J
    Eur J Pharm Sci; 2017 Nov; 109():446-454. PubMed ID: 28887230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolic profile and in vivo antischistosomal activity studies of (η(6)-praziquantel)Cr(CO)3 derivatives.
    Patra M; Ingram K; Leonidova A; Pierroz V; Ferrari S; Robertson MN; Todd MH; Keiser J; Gasser G
    J Med Chem; 2013 Nov; 56(22):9192-8. PubMed ID: 24219617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel.
    Sharma LK; Cupit PM; Goronga T; Webb TR; Cunningham C
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2469-72. PubMed ID: 24775301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of the oral praziquantel anthelmintic effect by cyclodextrin complexation.
    de Jesus MB; Pinto Lde M; Fraceto LF; Magalhães LA; Zanotti-Magalhães EM; de Paula E
    J Drug Target; 2010 Jan; 18(1):21-6. PubMed ID: 19624246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and characterization of a new solid form of praziquantel, an essential anthelmintic drug. Praziquantel racemic monohydrate.
    Salazar-Rojas D; Maggio RM; Kaufman TS
    Eur J Pharm Sci; 2020 Apr; 146():105267. PubMed ID: 32061654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of Praziquantel/Cyclodextrin Inclusion Complexation by NMR and LC-HRMS/MS: Mechanism, Solubility, Chemical Stability, and Degradation Products.
    Špehar TK; Pocrnić M; Klarić D; Bertoša B; Čikoš A; Jug M; Padovan J; Dragojević S; Galić N
    Mol Pharm; 2021 Nov; 18(11):4210-4223. PubMed ID: 34670371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment.
    de Souza AL; Andreani T; de Oliveira RN; Kiill CP; dos Santos FK; Allegretti SM; Chaud MV; Souto EB; Silva AM; Gremião MP
    Int J Pharm; 2014 Mar; 463(1):31-7. PubMed ID: 24370839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
    da Silva VBR; Campos BRKL; de Oliveira JF; Decout JL; do Carmo Alves de Lima M
    Bioorg Med Chem; 2017 Jul; 25(13):3259-3277. PubMed ID: 28495384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni.
    Lotfy WM; Hishmat MG; El Nashar AS; Abu El Einin HM
    Pharm Biol; 2015 Aug; 53(8):1214-9. PubMed ID: 25609146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanostructured Lipid Carriers as a Strategy to Improve the In Vitro Schistosomiasis Activity of Praziquantel.
    Kolenyak-Santos F; Garnero C; de Oliveira RN; de Souza AL; Chorilli M; Allegretti SM; Longhi MR; Chaud MV; Gremião MP
    J Nanosci Nanotechnol; 2015 Jan; 15(1):761-72. PubMed ID: 26328440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.
    El-Feky GS; Mohamed WS; Nasr HE; El-Lakkany NM; Seif El-Din SH; Botros SS
    Antimicrob Agents Chemother; 2015; 59(6):3501-8. PubMed ID: 25845870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of Schistosoma mansoni isolates having different drug sensitivity to praziquantel over several life cycle passages with and without therapeutic pressure.
    Sabra AN; Botros SS
    J Parasitol; 2008 Apr; 94(2):537-41. PubMed ID: 18564758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.